Immutep Announces Improving Results from Stage I of Phase II TACTI-002 Study

SYDNEY, Australia, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces new interim data from its ongoing Phase II TACTI-002 study. The data was presented in two poster presentations at the ESMO Virtual Congress 2020 on 17 September 2020 and relates to the cut-off date of 21 August 2020.

See the original post here:
Immutep Announces Improving Results from Stage I of Phase II TACTI-002 Study

CORRECTING and REPLACING – Zogenix Appoints Three Industry Leaders to Its Board of Directors

Correction: In this updated news release issued September 21, 2020 by Zogenix, Inc, the name of the organization, WorldWideWomen, has been corrected. The full corrected press release follows.

Read more here:
CORRECTING and REPLACING - Zogenix Appoints Three Industry Leaders to Its Board of Directors

Valneva Announces Retirement of Chief Financial Officer David Lawrence

Saint-Herblain (France), September 18, 2020 – Valneva SE (“Valneva”), a specialty vaccine company focused on prevention of diseases with major unmet needs, today announced the retirement of its Chief Financial Officer, David Lawrence, at the end of 2020.

More:
Valneva Announces Retirement of Chief Financial Officer David Lawrence

Pacific Biosciences Announces New Chief Financial Officer

MENLO PARK, Calif., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced the appointment of Susan G. Kim as Chief Financial Officer, effective as of September 28, 2020.

Read this article:
Pacific Biosciences Announces New Chief Financial Officer

Morphic Therapeutic to Present at the Jefferies Next Generation IBD Therapeutics Virtual Summit

WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced two presentations at the Jefferies Next Generation IBD Therapeutics Virtual Summit. Members of the Morphic management team are scheduled to participate in a panel discussion at 8:45 a.m. ET on Wednesday, September 23, 2020, as well as present a company overview at 1:00 p.m. ET on the same day.

Read more:
Morphic Therapeutic to Present at the Jefferies Next Generation IBD Therapeutics Virtual Summit

Dr. Jennifer Buell Speaks Live at Scientific American Inaugural Fireside Chat Series 18 Minutes With

LEXINGTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell, President and COO of Agenus, spoke to Jeremy Abbate, Publisher of Scientific American, in its inaugural fireside chat series 18 Minutes With on Wednesday September 16, 2020 at 4:00 p.m. EDT.

Read more from the original source:
Dr. Jennifer Buell Speaks Live at Scientific American Inaugural Fireside Chat Series 18 Minutes With

Saniona to Participate in Oppenheimer’s Virtual 2020 Fall Healthcare Life Sciences & MedTech Summit

PRESS RELEASE

Follow this link:
Saniona to Participate in Oppenheimer’s Virtual 2020 Fall Healthcare Life Sciences & MedTech Summit

ERYTECH establishes a financing facility with the implementation of an at-the-market program on Nasdaq with Cowen

LYON, France, Sept. 21, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq : ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances in red blood cells (the "Company"), today announced the implementation of an at-the-market program allowing the Company to issue and sell ordinary shares in the form of American Depositary Shares ("ADSs"), to eligible investors at market prices, with aggregate gross sales proceeds of up to $30,000,000 (subject to a regulatory limit of 20% dilution), from time to time, pursuant to the terms of a sales agreement with Cowen acting as sales agent.

Read the original here:
ERYTECH establishes a financing facility with the implementation of an at-the-market program on Nasdaq with Cowen

Zenith Provides Update Regarding Extension of its Filing Calendar

CALGARY, Alberta, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith” or the “Company”) today announces that, further to its August 26, 2020 press release, it continues to rely on blanket exemptions issued by provincial securities commissions due to the COVID-19 outbreak that permit the Company to extend the filing deadline of certain continuous disclosure documents for a period of up to 45 days.

Continue reading here:
Zenith Provides Update Regarding Extension of its Filing Calendar

Nicox Announces Senior Management Change

More here:
Nicox Announces Senior Management Change